Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Christopher Sweeney, MBBS


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Bladder cancer
  • Clinical trials
  • Hormone and chemotherapy
  • Kidney cancer
  • Prostate cancer
  • Testicular cancer

Contact Information

  • Appointments877-332-4294 (new)
    617-582-9725 (follow-up)
  • Office Phone Number617-582-7221
  • Fax617-632-2165

Board Certification:

  • Internal Medicine, 1997
  • Medical Oncology, 2000

Fellowship:

  • Indiana University, Hematology and Oncology

Residency:

  • Gundersen Lutheran Medical Center, Internal Medicine

Medical School:

  • University of Adelaide, Australia

Recent Awards:

  • Membership of the American Society of Clinical Oncology, Eastern Cooperative Oncology Group, and American Association for Cancer Research.
  • Chairman of the Hoosier Oncology Group 2005-2007
  • Program Committee and the Cancer Education Committee of the American Society of Clinical Oncology
  • Editorial Board, Journal of Clinical Oncology
  • Peer-reviewed funding from the National Institutes of Health and the Department of Defense, Lance Armstrong Foundation, and PhRMA.

Research

Preclinical drug development and drug evaluation, clinical trials in genitourinary malignancies (prostate, bladder, kidney, and testis cancer)

Dr. Sweeney has focused his academic career on the management of genitourinary malignancies, including prostate, bladder, testis, and renal cell cancer. His research interest has been primarily focused on drug development. This has included (i) design and conduct of phase I trials of new agents or new combinations that assess the safety and distribution of the drug in the body as well as the anti-cancer activity of the therapy; (ii) assessment of genetic variants and blood markers to try and define signatures that identify patients who are destined to benefit from a therapy; (iii) design and conduct of phase 2 and 3 clinical trials with a focus on bladder and prostate cancer and (iv) drug discovery and evaluation in the laboratory to guide clinical trial design.

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021 Aug 12; 13(16).
View in: PubMed

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 09; 22(9):1290-1300.
View in: PubMed

An integrated framework of plant form and function: the belowground perspective. New Phytol. 2021 10; 232(1):42-59.
View in: PubMed

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021 Jul 10; 398(10295):131-142.
View in: PubMed

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Netw Open. 2021 Jul 01; 4(7):e2116536.
View in: PubMed

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol. 2021 09; 32(9):1157-1166.
View in: PubMed

Root traits explain plant species distributions along climatic gradients yet challenge the nature of ecological trade-offs. Nat Ecol Evol. 2021 08; 5(8):1123-1134.
View in: PubMed

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2021 Jun 09.
View in: PubMed

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. Eur Urol. 2021 Sep; 80(3):275-279.
View in: PubMed

Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2021 May 18.
View in: PubMed

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 Aug 01; 39(22):2486-2496.
View in: PubMed

Metastatic Prostate Cancer: In Search of More Granularity. J Clin Oncol. 2021 Sep 10; 39(26):2968-2969.
View in: PubMed

A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate. 2021 Jul; 81(10):683-693.
View in: PubMed

NF-?B Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. Mol Cancer Res. 2021 07; 19(7):1137-1145.
View in: PubMed

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol. 2021 05 10; 39(14):1563-1574.
View in: PubMed

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552.
View in: PubMed

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 Apr; 2(4):444-456.
View in: PubMed

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol. 2021 05 10; 39(14):1553-1562.
View in: PubMed

Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. 2021 Sep; 155:165-171.
View in: PubMed

Root traits explain rhizosphere fungal community composition among temperate grassland plant species. New Phytol. 2021 02; 229(3):1492-1507.
View in: PubMed

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. Eur Urol Focus. 2020 Oct 06.
View in: PubMed

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open. 2020 10 01; 3(10):e2021692.
View in: PubMed

Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate. 2021 01; 81(1):50-57.
View in: PubMed

Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate. 2020 12; 80(16):1429-1437.
View in: PubMed

Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131.
View in: PubMed

Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer Prostatic Dis. 2021 06; 24(2):341-348.
View in: PubMed

Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. Mol Cancer Ther. 2020 10; 19(10):2155-2162.
View in: PubMed

A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. Radiother Oncol. 2020 11; 152:80-88.
View in: PubMed

When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. Eur Urol. 2021 05; 79(5):565-567.
View in: PubMed

Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. Eur Urol Oncol. 2020 12; 3(6):717-724.
View in: PubMed

A Call for Standardized Reporting of Adverse Events. Eur Urol. 2020 09; 78(3):481-482.
View in: PubMed

The fungal collaboration gradient dominates the root economics space in plants. Sci Adv. 2020 Jul; 6(27).
View in: PubMed

FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nat Protoc. 2020 08; 15(8):2503-2518.
View in: PubMed

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041.
View in: PubMed

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncol. 2020 04 01; 6(4):e196496.
View in: PubMed

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547.
View in: PubMed

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020 03; 31(3):412-421.
View in: PubMed

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3.
View in: PubMed

Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer. 2020 03 01; 126(5):986-993.
View in: PubMed

Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
View in: PubMed

Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. Eur Urol. 2020 03; 77(3):388-390.
View in: PubMed

Enzalutamide in Metastatic Prostate Cancer. Reply. N Engl J Med. 2019 10 10; 381(15):1494-1495.
View in: PubMed

The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. Eur Urol. 2019 12; 76(6):729-731.
View in: PubMed

Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. J Clin Oncol. 2019 11 10; 37(32):2961-2967.
View in: PubMed

Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic mice. Drug Dev Res. 2019 09; 80(6):824-830.
View in: PubMed

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019 07 11; 381(2):121-131.
View in: PubMed

DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. Radiat Res. 2019 08; 192(2):231-239.
View in: PubMed

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116.
View in: PubMed

AYA testis cancer: The unmet challenge. Pediatr Blood Cancer. 2019 08; 66(8):e27796.
View in: PubMed

Investigation of the skin microbiome: swabs vs. biopsies. Br J Dermatol. 2019 09; 181(3):572-579.
View in: PubMed

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Eur J Cancer. 2019 06; 114:128-136.
View in: PubMed

What Does Metastasis-Free Survival Actually Mean? J Clin Oncol. 2019 07 01; 37(19):1679-1680.
View in: PubMed

Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. J Med Internet Res. 2019 05 02; 21(5):e12044.
View in: PubMed

Body Mass Index and Outcomes in Germ-Cell Tumors. Clin Genitourin Cancer. 2019 08; 17(4):283-290.
View in: PubMed

Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncol. 2019 Apr 01; 5(4):514-522.
View in: PubMed

Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer. Eur Urol Focus. 2019 03; 5(2):111-113.
View in: PubMed

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 04; 20(4):518-530.
View in: PubMed

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019 07; 76(1):115-124.
View in: PubMed

Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. J Clin Oncol. 2019 04 01; 37(10):765-769.
View in: PubMed

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz002.
View in: PubMed

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019 09; 22(3):420-427.
View in: PubMed

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019 07; 76(1):89-97.
View in: PubMed

Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU Int. 2019 03; 123(3):385-387.
View in: PubMed

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 02 15; 125(4):524-532.
View in: PubMed

Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):584-590.
View in: PubMed

Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. Eur Urol Oncol. 2019 09; 2(5):475-482.
View in: PubMed

Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clin Genitourin Cancer. 2019 Feb; 17(1):32-37.
View in: PubMed

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. Eur Urol. 2019 01; 75(1):44-60.
View in: PubMed

Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors. Am J Clin Oncol. 2018 10; 41(10):949-952.
View in: PubMed

Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer. 2019 Feb; 17(1):58-64.e1.
View in: PubMed

Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 02; 75(2):285-293.
View in: PubMed

Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE-CSU. Allergy. 2018 Aug; 73(8):1724-1734.
View in: PubMed

Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next? Eur Urol. 2018 10; 74(4):420-421.
View in: PubMed

Interventional vitamin C: A strategy for attenuation of coagulopathy and inflammation in a swine multiple injuries model. J Trauma Acute Care Surg. 2018 07; 85(1S Suppl 2):S57-S67.
View in: PubMed

Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 10; 35(7):649-661.
View in: PubMed

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07.
View in: PubMed

ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018 07 02; 128(7):2979-2995.
View in: PubMed

Reply to J.J. Tao et al. J Clin Oncol. 2018 08 10; 36(23):2451.
View in: PubMed

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018 05 01; 29(5):1249-1257.
View in: PubMed

Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523.
View in: PubMed

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol. 2018 04 10; 36(11):1088-1095.
View in: PubMed

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018 06; 73(6):847-855.
View in: PubMed

NF-?B inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discov. 2018 Dec; 4:10.
View in: PubMed

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 04 10; 36(11):1080-1087.
View in: PubMed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018 02 20; 36(6):536-542.
View in: PubMed

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clin Genitourin Cancer. 2018 04; 16(2):130-134.
View in: PubMed

Reply to Y. Zhu et al. J Clin Oncol. 2018 02 10; 36(5):515-516.
View in: PubMed

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis. 2018 09; 21(3):306-318.
View in: PubMed

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382.
View in: PubMed

Current treatment strategies for advanced prostate cancer. Int J Urol. 2018 03; 25(3):220-231.
View in: PubMed

Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. Cancer. 2018 03 01; 124(5):925-933.
View in: PubMed

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018 02; 23(2):193-202.
View in: PubMed

Chemotherapy for oligometastatic prostate cancer. Curr Opin Urol. 2017 Nov; 27(6):553-558.
View in: PubMed

A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer. JCO Clin Cancer Inform. 2017 11; 1:1-15.
View in: PubMed

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res. 2017 Nov 15; 23(22):7072-7083.
View in: PubMed

Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene. 2018 01 11; 37(2):197-207.
View in: PubMed

Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clin Genitourin Cancer. 2017 Sep 08.
View in: PubMed

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017 09 20; 35(27):3097-3104.
View in: PubMed

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 10; 84:88-101.
View in: PubMed

Prostate cancer: A new standard-of-care for advanced-stage disease. Nat Rev Clin Oncol. 2017 10; 14(10):592-593.
View in: PubMed

Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clin Genitourin Cancer. 2017 Aug 03.
View in: PubMed

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann Oncol. 2017 08 01; 28(8):1692-1694.
View in: PubMed

The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
View in: PubMed

Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404]. Gynecol Oncol. 2017 12; 147(3):725.
View in: PubMed

Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413]. Gynecol Oncol. 2017 12; 147(3):726.
View in: PubMed

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211.
View in: PubMed

Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene. 2017 09 07; 36(36):5158-5167.
View in: PubMed

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104.
View in: PubMed

Predictors of growth kinetics and outcomes in small renal masses (SRM =4 cm in size): Tayside Active Surveillance Cohort (TASC) Study. Eur J Surg Oncol. 2017 Aug; 43(8):1589-1597.
View in: PubMed

"Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol. 2017 07; 72(1):1-3.
View in: PubMed

Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo. Radiat Res. 2017 05; 187(5):501-512.
View in: PubMed

Chronic Disease Management - The Patient's Perspective. Ir Med J. 2017 Feb 10; 110(2):511.
View in: PubMed

Racial Disparities in Prostate Cancer Outcome among Prostate-Specific Antigen Screening Eligible Populations in the United States. Ann Oncol. 2017 Feb 08.
View in: PubMed

Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 05 01; 123(9):1536-1544.
View in: PubMed

Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer. J Oncol Pract. 2017 01; 13(1):9-18.
View in: PubMed

Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev. 2017 Feb; 53:79-97.
View in: PubMed

Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. Eur Urol Focus. 2016 Dec; 2(5):463-464.
View in: PubMed

Transmission of severe haemophilia A by in vitro fertilization with donated eggs. Haemophilia. 2017 09; 23(5):e451-e453.
View in: PubMed

Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016 11 30; 540(7631):114-118.
View in: PubMed

Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. Eur Urol Focus. 2016 Dec; 2(5):488-498.
View in: PubMed

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2017 01; 18(1):132-142.
View in: PubMed

Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3.
View in: PubMed

Age =40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. Eur Urol Focus. 2017 12; 3(6):621-628.
View in: PubMed

Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700.
View in: PubMed

Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer. 2016 Oct 15; 122(20):3127-3135.
View in: PubMed

Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):726-734.
View in: PubMed

National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377.
View in: PubMed

CT restaging of testicular germ cell tumors: The incidence of isolated pelvic metastases. Eur J Radiol. 2016 Aug; 85(8):1439-44.
View in: PubMed

A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
View in: PubMed

Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci U S A. 2016 May 31; 113(22):6259-64.
View in: PubMed

Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 09; 70(3):410-2.
View in: PubMed

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3.
View in: PubMed

Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med. 2016 06; 22(6):685-91.
View in: PubMed

Computational Reconstruction of NF?B Pathway Interaction Mechanisms during Prostate Cancer. PLoS Comput Biol. 2016 Apr; 12(4):e1004820.
View in: PubMed

Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016 06 01; 34(16):1905-12.
View in: PubMed

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol. 2016 06 01; 34(16):1913-20.
View in: PubMed

Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8.
View in: PubMed

Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2016 06; 19(2):139-44.
View in: PubMed

Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016 Dec; 118(6):919-926.
View in: PubMed

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene. 2016 Mar 03; 35(9):1206.
View in: PubMed

Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene. 2016 09 08; 35(36):4807-15.
View in: PubMed

Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. N Engl J Med. 2016 01 21; 374(3):287.
View in: PubMed

Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. J Clin Oncol. 2016 Mar 01; 34(7):714-20.
View in: PubMed

Approach to Oligometastatic Prostate Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:119-29.
View in: PubMed

Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. J Urol. 2016 07; 196(1):95-100.
View in: PubMed

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016 Feb; 17(2):243-256.
View in: PubMed

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
View in: PubMed

It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2016 08; 70(2):263-4.
View in: PubMed

Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clin Cancer Res. 2016 05 01; 22(9):2183-9.
View in: PubMed

The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy. JAMA Oncol. 2015 Dec; 1(9):1270-1.
View in: PubMed

Diagnosis and Treatment of Testicular Cancer: A Clinician's Perspective. Surg Pathol Clin. 2015 Dec; 8(4):717-23.
View in: PubMed

Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22.
View in: PubMed

Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res. 2016 Feb 01; 22(3):765-772.
View in: PubMed

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol. 2016 Feb 01; 34(4):345-51.
View in: PubMed

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015 Dec; 107(12):djv261.
View in: PubMed

Relationship Between the Pathologic Subtype/Initial Stage and Microliths in Testicular Germ Cell Tumors. J Ultrasound Med. 2015 Nov; 34(11):1977-82.
View in: PubMed

LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells. Oncogene. 2016 06 02; 35(22):2932-47.
View in: PubMed

Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32.
View in: PubMed

Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85.
View in: PubMed

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. J Clin Oncol. 2015 Sep 20; 33(27):3018-28.
View in: PubMed

Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101.
View in: PubMed

Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity. Clin Cancer Res. 2015 Dec 15; 21(24):5578-87.
View in: PubMed

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373(8):737-46.
View in: PubMed

Approach to risk stratification in testicular germ cell tumors: a primer for radiologists. Abdom Imaging. 2015 Aug; 40(6):1871-86.
View in: PubMed

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35.
View in: PubMed

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene. 2016 Mar 03; 35(9):1143-52.
View in: PubMed

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncol. 2015 Jul; 1(4):495-504.
View in: PubMed

Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 2015 Dec; 13(6):525-30.e1-3.
View in: PubMed

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015 Aug; 26(8):1589-604.
View in: PubMed

[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Transl Oncol. 2015 Jun; 8(3):147-53.
View in: PubMed

Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8.
View in: PubMed

Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015 Jul; 33(7):330.e19-25.
View in: PubMed

A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015 Jul; 26(7):1396-401.
View in: PubMed

A reproducible approach to high-throughput biological data acquisition and integration. PeerJ. 2015; 3:e791.
View in: PubMed

PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8.
View in: PubMed

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2015 Aug 01; 21(15):3420-7.
View in: PubMed

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015 Jun; 26(6):1230-1237.
View in: PubMed

Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treat Rev. 2015 Apr; 41(4):332-40.
View in: PubMed

Management of metastatic hormone-sensitive prostate cancer. Curr Urol Rep. 2015 Mar; 16(3):14.
View in: PubMed

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906.
View in: PubMed

Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9.
View in: PubMed

Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16.
View in: PubMed

NF-?B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death Dis. 2015 Jan 22; 6:e1608.
View in: PubMed

Insights into E3805: the CHAARTED trial. Future Oncol. 2015; 11(6):897-9.
View in: PubMed

(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging. 2015; 5(1):72-82.
View in: PubMed

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.
View in: PubMed

Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65.
View in: PubMed

'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1253-6.
View in: PubMed

Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13.
View in: PubMed

Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. AJR Am J Roentgenol. 2014 Oct; 203(4):W415-20.
View in: PubMed

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9.
View in: PubMed

The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9.
View in: PubMed

Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92.
View in: PubMed

Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8.
View in: PubMed

Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91.
View in: PubMed

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
View in: PubMed

Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95.
View in: PubMed

Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7319-24.
View in: PubMed

Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21.
View in: PubMed

SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
View in: PubMed

Elevated IL-8, TNF-a, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014 Jun; 74(8):820-8.
View in: PubMed

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67(2):310-8.
View in: PubMed

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRa) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar; 73(3):595-604.
View in: PubMed

Preface. Prostate cancer. Hematol Oncol Clin North Am. 2013 Dec; 27(6):xi-xii.
View in: PubMed

A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Ann Oncol. 2014 Feb; 25(2):331-8.
View in: PubMed

Developing and promoting evidence-based use of granulocyte colony stimulating factors (GCSF) in the palliative chemotherapy setting. J Clin Oncol. 2013 Nov; 31(31_suppl):172.
View in: PubMed

Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014 Feb; 74(3):225-34.
View in: PubMed

Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clin Genitourin Cancer. 2014 Feb; 12(1):33-40.e4.
View in: PubMed

An association between rainfall and bovine TB in Wicklow, Ireland. Vet Rec. 2013 Nov 09; 173(18):452.
View in: PubMed

Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol. 2013 Oct 01; 31(28):3490-3.
View in: PubMed

Enhanced seasonal exchange of CO2 by northern ecosystems since 1960. Science. 2013 Sep 06; 341(6150):1085-9.
View in: PubMed

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014 May 22; 33(21):2790-800.
View in: PubMed

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013 Aug 15; 119(16):2990-8.
View in: PubMed

Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. J Clin Oncol. 2013 Feb 20; 31(6_suppl):33.
View in: PubMed

A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). J Clin Oncol. 2013 Feb 20; 31(6_suppl):324.
View in: PubMed

Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):397.
View in: PubMed

A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):325.
View in: PubMed

A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. J Clin Oncol. 2013 Feb 20; 31(6_suppl):278.
View in: PubMed

Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol. 2013 Feb 20; 31(6_suppl):255.
View in: PubMed

Prostate cancer therapy: going forwards by going backwards. Lancet Oncol. 2013 Feb; 14(2):104-5.
View in: PubMed

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9.
View in: PubMed

Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond). 2013 May; 8(5):687-98.
View in: PubMed

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
View in: PubMed

Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013 Nov; 27(11):1440-3.
View in: PubMed

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012 Apr 04; 4(128):128ra39.
View in: PubMed

Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2012 Oct 01; 84(2):383-9.
View in: PubMed

Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT). J Clin Oncol. 2012 Feb 10; 30(5_suppl):191.
View in: PubMed

Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group). J Clin Oncol. 2012 Feb 10; 30(5_suppl):373.
View in: PubMed

Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):56.
View in: PubMed

Use of elevated baseline IL-8, CCL-2, and TNFa to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). J Clin Oncol. 2012 Feb 10; 30(5_suppl):13.
View in: PubMed

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012 Dec; 30(6):2303-17.
View in: PubMed

Inhibition of NF-?B and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radic Biol Med. 2011 Dec 15; 51(12):2249-58.
View in: PubMed

Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011 Sep; 186(3):865-72.
View in: PubMed

Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: implications for future genomic research in minority populations. Cancer. 2012 Feb 15; 118(4):1075-82.
View in: PubMed

Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4594.
View in: PubMed

A case-control study examining associations of germ-line oxidative DNA repair single-nucleotide polymorphisms (SNPs) with lethal prostate cancer (PCa) risk. J Clin Oncol. 2011 May 20; 29(15_suppl):4645.
View in: PubMed

Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS194.
View in: PubMed

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol. 2011 May 20; 29(15_suppl):4516.
View in: PubMed

A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-?B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10):2481-94.
View in: PubMed

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011 Apr 20; 29(12):1525-30.
View in: PubMed

Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res. 2011 Jan 15; 17(2):363-71.
View in: PubMed

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy. Am Soc Clin Oncol Educ Book. 2011; 2011:171-176.
View in: PubMed

Evaluation of nuclear factor ?B and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int. 2011 Jul; 108(2 Pt 2):E51-8.
View in: PubMed

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol. 2011 Jun; 22(6):1413-1419.
View in: PubMed

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010 Dec 01; 304(21):2373-80.
View in: PubMed

A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Dec; 88(6):818-23.
View in: PubMed

Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol. 2011 Apr; 22(4):801-807.
View in: PubMed

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol. 2010 Oct 10; 28(29):4513-20.
View in: PubMed

OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology. 2010 Aug 03; 75(5):411-8.
View in: PubMed

A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer. 2010 Aug 01; 116(15):3595-602.
View in: PubMed

A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. Prostate. 2010 Jul 01; 70(10):1074-86.
View in: PubMed

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec; 29(6):1465-74.
View in: PubMed

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemother Pharmacol. 2011 Feb; 67(2):431-8.
View in: PubMed

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res. 2010 May 01; 16(9):2677-87.
View in: PubMed

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 Aug; 66(3):441-8.
View in: PubMed

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010 Jul; 66(2):345-56.
View in: PubMed

A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol. 2009 Dec; 20(12):1971-6.
View in: PubMed

A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. J Clin Oncol. 2009 May 20; 27(15_suppl):5018.
View in: PubMed

A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):3025.
View in: PubMed

Testosterone therapy in castrate-resistant prostate cancer: a possible new approach. Eur Urol. 2009 Aug; 56(2):245-6.
View in: PubMed

Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells. Radiat Res. 2009 Apr; 171(4):389-96.
View in: PubMed

Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol. 2009 Jan 20; 27(3):460-3.
View in: PubMed

Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas. 2008 Oct; 37(3):e45-53.
View in: PubMed

Lessons learned from development of docetaxel. Expert Opin Drug Metab Toxicol. 2008 Jul; 4(7):1007-19.
View in: PubMed

Oncology outpatient and provider responses to a computerized symptom assessment system. Oncol Nurs Forum. 2008 Jul; 35(4):661-9.
View in: PubMed

LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene. 2008 Sep 25; 27(43):5741-52.
View in: PubMed

A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367. J Clin Oncol. 2008 May 20; 26(15_suppl):16019.
View in: PubMed

Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): A phase I dose-finding study. J Clin Oncol. 2008 May 20; 26(15_suppl):3562.
View in: PubMed

Effect of the C3435T genetic polymorphism in MDR1 on etoposide pharmacokinetics. J Clin Oncol. 2008 May 20; 26(15_suppl):2500.
View in: PubMed

Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). J Clin Oncol. 2008 May 20; 26(15_suppl):3523.
View in: PubMed

Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5173.
View in: PubMed

Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):2564.
View in: PubMed

A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis. J Clin Oncol. 2008 May 20; 26(15_suppl):14521.
View in: PubMed

Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3- kinase (PI3K) inhibitor in patients with solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):14532.
View in: PubMed

AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3570.
View in: PubMed

Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFRa in patients with advanced solid malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):14617.
View in: PubMed

A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res. 2008 Feb 15; 14(4):1131-7.
View in: PubMed

A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. J Biopharm Stat. 2008; 18(6):1150-77.
View in: PubMed

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15; 110(12):2628-39.
View in: PubMed

Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. Radiat Res. 2007 Dec; 168(6):689-97.
View in: PubMed

Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications. Future Oncol. 2007 Dec; 3(6):665-82.
View in: PubMed

Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008 Apr; 101(8):937-43.
View in: PubMed

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007 Dec 15; 110(13):4427-35.
View in: PubMed

Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer. J Surg Res. 2007 Nov; 143(1):169-76.
View in: PubMed

Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. . 2007 Jun; 6(6):1736-44.
View in: PubMed

Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res. 2007 May; 6(5):1822-32.
View in: PubMed

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81.
View in: PubMed

Notch signaling and vascular cell fate--how vascular cells respond to stress. Wien Klin Wochenschr. 2007; 119(11-12 Suppl 1):7-10.
View in: PubMed

The case for systemic therapy alone for prostate cancer. J Urol. 2006 Dec; 176(6 Pt 2):S42-6.
View in: PubMed

The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 01; 848(2):379-83.
View in: PubMed

Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat. 2007 Aug; 104(2):197-209.
View in: PubMed

Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6094-9.
View in: PubMed

Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate. 2006 Oct 01; 66(14):1498-511.
View in: PubMed

ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol. 2006 Aug; 4(8):588-90.
View in: PubMed

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006 Jul 20; 24(21):3451-7.
View in: PubMed

Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC): A Hoosier Oncology Group phase II study-Preliminary analysis. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4644.
View in: PubMed

Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3051.
View in: PubMed

Metabolic syndrome predicts for shorter response to hormonal therapy in prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4554.
View in: PubMed

Erlotinib-associated rash correlates with plasma levels at steady state. J Clin Oncol. 2006 Jun 20; 24(18_suppl):13008.
View in: PubMed

Looking for new targets for prostate cancer therapy: Nuclear factor kappa B and CXCR4 co-expression in prostate specimens from RTOG-8610. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14578.
View in: PubMed

The influence of body mass index (BMI) on outcome in patients with advanced germ cell tumors (GCT). J Clin Oncol. 2006 Jun 20; 24(18_suppl):14594.
View in: PubMed

A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors. Cancer Chemother Pharmacol. 2007 Feb; 59(2):261-8.
View in: PubMed

Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1966-9.
View in: PubMed

Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res. 2006 Jan 15; 12(2):536-42.
View in: PubMed

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006 Feb 01; 24(4):552-62.
View in: PubMed

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6625-33.
View in: PubMed

A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology. 2005; 69(1):63-70.
View in: PubMed

Germ cell tumors: an update of recent data and review of active protocols in stage I and metastatic disease. Urol Oncol. 2005 Jul-Aug; 23(4):293-302.
View in: PubMed

Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: Follow-up clinical results from ECOG 7897. J Clin Oncol. 2005 Jun; 23(16_suppl):4501.
View in: PubMed

Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy. J Clin Oncol. 2005 Jun; 23(16_suppl):4624.
View in: PubMed

A multicenter randomized phase II study of docetaxel (D) plus vinorelbine (VRB) and docetaxel plus estramustine (EMP) in combination for the treatment of hormone refractory prostate cancer (HRPC): HOG GU-0009. J Clin Oncol. 2005 Jun; 23(16_suppl):4568.
View in: PubMed

The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. . 2005 Jun; 4(6):1004-12.
View in: PubMed

Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. . 2005 Apr; 4(4):587-94.
View in: PubMed

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol. 2005 Feb 20; 23(6):1185-91.
View in: PubMed

Can tumor angiogenesis be inhibited without resistance? EXS. 2005; (94):95-112.
View in: PubMed

CYP1A1, cigarette smoking, and colon and rectal cancer. Am J Epidemiol. 2004 Nov 01; 160(9):842-52.
View in: PubMed

Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res. 2004 Aug 15; 10(16):5501-7.
View in: PubMed

Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs. 2004 Aug; 22(3):299-305.
View in: PubMed

A phase II study of venlafaxine for the treatment of hot flashes in men undergoing androgen deprivation for prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8148.
View in: PubMed

A dose escalation and pharmacokinetic (PK) trial of weekly docetaxel combined with daily erlotinib in adult cancer patients. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2119.
View in: PubMed

Pharmacokinetics (PK) of arsenic trioxide in cancer patients (pts) with renal dysfunction: Preliminary results. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2018.
View in: PubMed

A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2017.
View in: PubMed

A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2069.
View in: PubMed

Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res. 2004 Jul-Aug; 24(4):2135-40.
View in: PubMed

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004 Jun 01; 22(11):2122-32.
View in: PubMed

A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res. 2004 May 15; 10(10):3265-72.
View in: PubMed

PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res. 2004 Feb 15; 10(4):1333-7.
View in: PubMed

Negative regulation of ErbB family receptor tyrosine kinases. Br J Cancer. 2004 Jan 26; 90(2):289-93.
View in: PubMed

The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int. 2004 Jan; 93(1):143-50.
View in: PubMed

Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer. 2003 Nov 01; 98(9):1830-6.
View in: PubMed

Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res. 2003 Sep 15; 63(18):6063-8.
View in: PubMed

Why cyclooxygenase-2 inhibition plus chemotherapy? Am J Clin Oncol. 2003 Aug; 26(4):S122-5.
View in: PubMed

Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol. 2003 Jun; 14(6):873-80.
View in: PubMed

Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors. Am J Clin Oncol. 2003 Apr; 26(2):200-2.
View in: PubMed

The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol. 2003 Jan; 14(1):20-8.
View in: PubMed

Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med. 2003 Jan; 9(1):24-9.
View in: PubMed

Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer. 2002 Oct 15; 95(8):1650-5.
View in: PubMed

Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. Prostate. 2002 Sep 15; 53(1):69-76.
View in: PubMed

Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. J Urol. 2002 Jul; 168(1):193.
View in: PubMed

Selenomethionine induction of DNA repair response in human fibroblasts. Oncogene. 2002 May 23; 21(23):3663-9.
View in: PubMed

Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene. 2002 Mar 27; 21(13):2066-78.
View in: PubMed

A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol. 2002 Mar; 13(3):435-40.
View in: PubMed

Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer. 2002 Jan 01; 94(1):104-10.
View in: PubMed

Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev. 2002; 26(3):238-44.
View in: PubMed

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma . Cancer. 2001 Nov 15; 92(10):2639-47.
View in: PubMed

The role of human glutathione S-transferases (hGSTs) in the detoxification of the food-derived carcinogen metabolite N-acetoxy-PhIP, and the effect of a polymorphism in hGSTA1 on colorectal cancer risk. Mutat Res. 2001 Oct 01; 482(1-2):3-10.
View in: PubMed

Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 2001 Oct 01; 61(19):7130-5.
View in: PubMed

Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep; 298(3):976-85.
View in: PubMed

Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry. 2001 Aug; 71(2):149-54.
View in: PubMed

History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity. Semin Urol Oncol. 2001 Aug; 19(3):170-9.
View in: PubMed

Research opportunities in palliative medicine. Tex Med. 2001 Aug; 97(8):64-8.
View in: PubMed

Changing patterns of symptom control and palliative care paper presentations at the annual meeting of the American Society of Clinical Oncology. J Clin Oncol. 2001 Jul 15; 19(14):3438-9.
View in: PubMed

The development of palliative care at the University of Texas M.D. Anderson Cancer Center. Support Care Cancer. 2001 Jul; 9(5):330-4.
View in: PubMed

Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol. 2001 Jun 01; 19(11):2883-5.
View in: PubMed

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001 Apr 15; 61(8):3369-72.
View in: PubMed

Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem. 2001 Jun 22; 276(25):22685-98.
View in: PubMed

Localization and modulation of ErbB receptor tyrosine kinases. Curr Opin Cell Biol. 2001 Apr; 13(2):125-30.
View in: PubMed

Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001 Feb 15; 19(4):1195-206.
View in: PubMed

Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene. 2000 Nov 20; 19(49):5568-73.
View in: PubMed

Cachexia and asthenia in cancer patients. Lancet Oncol. 2000 Nov; 1:138-47.
View in: PubMed

Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. 2000 Oct 15; 60(20):5621-4.
View in: PubMed

Ligand discrimination in signaling through an ErbB4 receptor homodimer. J Biol Chem. 2000 Jun 30; 275(26):19803-7.
View in: PubMed

Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol. 2000 Jun; 163(6):1721-4.
View in: PubMed

Differential survival related to smoking among patients with renal cell carcinoma. Epidemiology. 2000 May; 11(3):344-6.
View in: PubMed

Chemotherapy in non-small cell lung cancer. Invest New Drugs. 2000 May; 18(2):157-86.
View in: PubMed

Glutathione S-transferase M1, T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control study. Cancer Epidemiol Biomarkers Prev. 2000 Apr; 9(4):449-54.
View in: PubMed

Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control. 2000 Mar; 11(3):231-8.
View in: PubMed

Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000 Feb; 21(2):139-46.
View in: PubMed

Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. J Clin Oncol. 2000 Jan; 18(2):358-62.
View in: PubMed

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer. 1999 Aug 01; 86(3):514-8.
View in: PubMed

Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. Int J Oncol. 1999 Aug; 15(2):271-9.
View in: PubMed

Nephroblastoma-like tumors in patients with testicular germ cell tumors. Am J Surg Pathol. 1998 Sep; 22(9):1107-14.
View in: PubMed

Treatment of advanced (stages III and IV) non-small-cell lung cancer. Curr Probl Cancer. 1998 Mar-Apr; 22(2):85-132.
View in: PubMed

The relationship between proteoglycan synthesis in Swarm chondrocytes and pathways of cellular energy and UDP-sugar metabolism. Carbohydr Res. 1994 Mar 04; 255:255-70.
View in: PubMed

Cavernous haemangiomas (angiomas) of the brain: clinically significant lesions. Australas Radiol. 1993 May; 37(2):147-55.
View in: PubMed

Hyaluronan and hyaluronan-binding proteins in cartilaginous tissues. Ciba Found Symp. 1989; 143:107-16; discussion 117-20, 281-5.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top